Altimmune (ALT) Stock Price
Altimmune Price
Revenue at Altimmune has contracted by 18.2% per year over the past 19 years to 41,000.00 USD. For Altimmune, the net margin of -214,861.0% is down versus -2,201.6% a few years ago. At today's price the dividend yield works out to roughly 26,697.25%. The consensus 12-month price target for Altimmune is 20.40 USD, about 523.9% above where the stock trades today. Of 15 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 26% above its 52-week low.
Altimmune stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Altimmune over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Altimmune stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Altimmune's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Altimmune Price |
|---|---|
| 9/11/2026 | 3.27 USD |
| 9/10/2026 | 3.29 USD |
| 9/9/2026 | 3.35 USD |
| 9/8/2026 | 3.38 USD |
| 9/4/2026 | 3.42 USD |
| 9/3/2026 | 3.23 USD |
| 9/2/2026 | 3.28 USD |
| 9/1/2026 | 3.09 USD |
| 8/31/2026 | 3.11 USD |
| 8/30/2026 | 3.10 USD |
| 8/28/2026 | 3.09 USD |
| 8/27/2026 | 3.17 USD |
| 8/26/2026 | 3.15 USD |
| 8/25/2026 | 3.20 USD |
| 8/24/2026 | 3.12 USD |
| 8/21/2026 | 3.11 USD |
| 8/20/2026 | 2.95 USD |
| 8/19/2026 | 3.10 USD |
| 8/18/2026 | 2.99 USD |
| 8/14/2026 | 2.94 USD |
| 8/13/2026 | 2.88 USD |
| 8/12/2026 | 3.16 USD |
| 8/10/2026 | 3.05 USD |
| 8/7/2026 | 3.08 USD |
| 8/6/2026 | 3.01 USD |
| 8/5/2026 | 3.03 USD |
| 8/4/2026 | 2.98 USD |
| 8/3/2026 | 3.00 USD |
| 7/31/2026 | 2.84 USD |
| 7/30/2026 | 2.98 USD |
Altimmune Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Altimmune Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.00 | 5.00 | – | 10.00 | 5.00 | 8.00 | 4.00 | – | – | – | – | – | – | 94.00 | 51.00 | 165.00 |
| – | -50.00 | – | – | -50.00 | 60.00 | -50.00 | – | – | – | – | – | – | – | -45.74 | 223.53 |
| 50.00 | -20.00 | – | -80.00 | 100.00 | -312.50 | 100.00 | – | – | – | – | – | – | 100.00 | 100.00 | 100.00 |
| 5.00 | -1.00 | -18.00 | -8.00 | 5.00 | -25.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 94.00 | 51.00 | 165.00 |
| -3.00 | -11.00 | -51.00 | -45.00 | -21.00 | -54.00 | -96.00 | -87.00 | -95.00 | -103.00 | -94.00 | – | -15.00 | -56.00 | -30.00 | -99.00 |
| -30.00 | -220.00 | – | -450.00 | -420.00 | -675.00 | -2,400.00 | – | – | – | – | – | – | -59.57 | -58.82 | -60.00 |
| -3.00 | 193.00 | -46.00 | -39.00 | -20.00 | -49.00 | -97.00 | -84.00 | -88.00 | -95.00 | -88.00 | -40.00 | -49.00 | -52.00 | -54.00 | -50.00 |
| -66.67 | -6,533.33 | -123.83 | -15.22 | -48.72 | 145.00 | 97.96 | -13.40 | 4.76 | 7.95 | -7.37 | -54.55 | 22.50 | 6.12 | 3.85 | -7.41 |
| – | – | 873.00 | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 0.21 | 0.23 | 0.67 | 9.49 | 15.11 | 38.92 | 41.71 | 50.03 | 58.44 | 71.26 | 100.61 | 100.61 | 100.61 | 100.61 | 100.61 | 100.61 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Altimmune generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Altimmune retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Altimmune's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Altimmune has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Altimmune's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Altimmune stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Altimmune Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Altimmune business model & stock analysis
Altimmune SWOT Analysis
Strengths
Altimmune Inc has a strong intellectual property portfolio, which includes patents and proprietary technologies that provide significant competitive advantage in the pharmaceutical industry.
The company's experienced management team and skilled workforce contribute to its expertise in vaccine development and immunotherapeutics.
Altimmune Inc has established partnerships with leading organizations and institutions, fostering collaboration and enhancing its research and development capabilities.
Weaknesses
Altimmune Inc relies heavily on a few key products, which increases its vulnerability to market fluctuations and regulatory challenges.
The company's limited financial resources may hinder its ability to invest in research and development, marketing, and expansion into new markets.
Altimmune Inc has a relatively small market share compared to some of its larger competitors, making it more difficult to penetrate established markets.
Opportunities
The growing demand for vaccines and immunotherapeutics presents significant opportunities for Altimmune Inc to expand its product portfolio and increase market share.
Advancements in technology and the increasing awareness of the importance of preventive healthcare create opportunities for the company to develop innovative solutions and gain a competitive edge.
Altimmune Inc can explore strategic partnerships and collaborations to access additional resources, expertise, and new markets.
Threats
The pharmaceutical industry is highly regulated, and changes in regulations and compliance requirements can pose challenges and increase costs for Altimmune Inc.
Intense competition from larger pharmaceutical companies with established brands and resources poses a threat to Altimmune Inc's market share and growth.
The ongoing COVID-19 pandemic has created a competitive landscape with increased focus on vaccine development, potentially increasing competition and reducing the market opportunities for Altimmune Inc.
Altimmune Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Altimmune Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Altimmune historical P/E ratio, EBIT multiple, and P/S ratio
Altimmune annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Altimmune shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Altimmune stock splits
Altimmune Dividend History
2 years of dividend payments
Altimmune dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Altimmune forecasts and price targets in September 2026
Analyst Price Targets 2026Altimmune Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/18/2026 | Maintained | Buy | – | |
| 5/14/2026 | Maintained | Market Outperform | – | |
| 3/16/2026 | Maintained | Buy | – | |
| 3/6/2026 | Maintained | Buy | – | |
| 11/7/2025 | Maintained | Market Outperform | – | |
| 10/20/2025 | Maintained | Buy | – | |
| 10/10/2025 | Maintained | Buy | – | |
| 8/13/2025 | Maintained | Buy | 49 | |
| 8/13/2025 | Maintained | Buy | – | |
| 8/13/2025 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Altimmune Earnings Calls
Altimmune Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.14USD | - | 0.00USD | - | 2026 Q2 |
| 5/13/2026 | -0.25USD | - | 717.00USD | - | 2026 Q1 |
| 2/25/2026 | -0.06USD | - | 717.00USD | - | 2025 Q4 |
| 8/7/2025 | -0.33USD | - | 1,262.00USD | - | 2025 Q2 |
| 11/12/2024 | -0.36USD | - | 838.00USD | - | 2024 Q3 |
| 5/9/2024 | -0.46USD | - | 0.00USD | - | 2024 Q1 |
| 2/26/2024 | -0.39USD | - | 2,161.00USD | - | 2023 Q4 |
| 11/8/2023 | -0.56USD | - | 507.00USD | - | 2023 Q3 |
| 8/9/2023 | -0.59USD | - | 1.69 MUSD | - | 2023 Q2 |
| 5/10/2023 | -0.59USD | - | 1.69 MUSD | - | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Altimmune stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Altimmune shareholder structure
| % | Name |
|---|---|
28.71029% | |
27.11138% | |
17.03938% | |
14.08383% | |
11.51741% | |
10.32382% |
Altimmune Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
9.99% | SEC ↗ | |
9.61% | SEC ↗ | |
7.80% | SEC ↗ | |
7.60% | SEC ↗ | |
7.50% | SEC ↗ | |
7.47% | SEC ↗ | |
7.47% | SEC ↗ | |
7.47% | SEC ↗ | |
7.47% | SEC ↗ | |
7.40% | SEC ↗ |
Altimmune Executives and Management Board
16 members · avg. age 67 · 25 % women
Dr. Vipin Garg (68)
President, Chief Executive Officer, Director · since 2018
6.09 M USD
Management
Mr. Raymond Jordt (52)
Chief Business Officer
Dr. M. Scott Harris (71)
Chief Medical Officer
Dr. M. Scot Roberts (66)
Chief Scientific Officer
Mr. Gregory Weaver (69)
Chief Financial Officer
Dr. Christophe Arbet-Engels
Chief Medical Officer
Ms. Linda Richardson (61)
Chief Commercial Officer
Board of Directors
Dr. Mitchel Sayare (77)
Independent Director · since 2010
Mr. Philip Hodges (57)
Independent Director
Mr. Wayne Pisano (70)
Independent Director
Brig. Gen. (Retd.) Klaus Schafer (75)
Independent Director
Mr. John Gill (73)
Independent Director · since 2007
Dr. Catherine Sohn (72)
Independent Director
Frequently asked questions about Altimmune
Altimmune Inc is a biopharmaceutical company with a business model focused on developing and commercializing novel immunotherapeutic products. The company aims to address various diseases and medical conditions through innovative vaccine technologies and immune modulation platforms. Altimmune Inc is committed to advancing its proprietary pipeline, leveraging its expertise in immunology and vaccine development. With a strong emphasis on research and development, Altimmune Inc strives to bring novel treatments to market that can positively impact the lives of patients worldwide.
Altimmune Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Altimmune Inc in the market include companies such as Inovio Pharmaceuticals, VBI Vaccines, Novavax, and Moderna Inc.
Altimmune Inc is a biopharmaceutical company focused on developing and commercializing immunotherapeutic products. Founded in 1997, Altimmune has a rich history of innovation in the field of immunology. The company specializes in the development of novel vaccines and immune-modulating therapies to combat infectious diseases. Altimmune's proprietary platform technologies enable the rapid design and development of next-generation immunotherapies. With a strong commitment to scientific research and development, Altimmune aims to transform the treatment landscape by addressing unmet medical needs. With its experienced team and extensive portfolio, Altimmune Inc is poised to make a significant impact on the global healthcare industry.
Altimmune Inc has achieved significant milestones in its journey. Some noteworthy accomplishments include the successful completion of Phase 2 clinical trials for its lead product candidate, AdCOVID, a single-dose intranasal COVID-19 vaccine. The company has also demonstrated the effectiveness of NasoShield, a vaccine for anthrax, in preclinical studies. Altimmune Inc has further enhanced its portfolio by acquiring Spitfire Pharma, a biopharmaceutical company focused on liver diseases. Additionally, the company has established collaborations with leading organizations, including the University of Alabama and the National Institutes of Health, to advance its innovative pipeline. These milestones highlight Altimmune Inc's dedication to advancing novel therapies and its potential for future growth in the biopharmaceutical industry.
Altimmune Inc is primarily present in the United States.
Altimmune Inc represents a core value of innovation and commitment to transformative medical solutions. With a strong corporate philosophy focused on advancing novel therapies, Altimmune Inc continuously strives to improve patient outcomes through groundbreaking immunotherapies. The company's dedication to scientific excellence and rigorous research enables the development of cutting-edge vaccine candidates, including intranasal vaccines to combat infectious diseases. Altimmune Inc's vision encompasses pioneering approaches in immunology and the goal of addressing unmet medical needs worldwide. By leveraging its expertise, Altimmune Inc remains at the forefront of medical advancements, exemplifying a steadfast commitment to improving global health.
Analysts currently set an average price target of 18.67 USD for the Altimmune stock (median: 20.40 USD), implying +470.8 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Altimmune stock: 12 recommend buying, 2 holding and 1 selling.
Converted at the current exchange rate, the Altimmune share trades at 2.82 EUR (3.27 USD).
The Altimmune share (ALT) is listed on 5 stock exchanges, including: NASDAQ (ALT), Frankfurt (3G0.F), München (3G0.MU), Düsseldorf (3G0.DU), London (0A4C.L).
The company Altimmune Inc. is a biopharmaceutical company specializing in the development of immunotherapies and vaccines for various diseases. Its business model is based on innovative research and development to meet the increasingly complex challenges of the medical industry. The company operates in three business areas - Immundevelopment, Vaxine, and Altimmune UK. Immundevelopment focuses on the research of immunotherapies and viral infections such as hepatitis B, HIV, and influenza. Vaxine develops vaccines against flu, anthrax, MERS, RSV, and COVID-19. Altimmune UK is increasingly focused on the field of neuroscience and oncology. Altimmune is divided into two pillars, immunotherapy and vaccine development. The two pillars work closely together to accelerate and improve the development of therapies and vaccines. In the immunotherapy pillar, treatments are being researched that stimulate the immune system to fight against various diseases. In the vaccine development, Altimmune produces vaccines that induce active immunization against certain diseases. One of Altimmune's most important products is NasoVAX, an intranasally administered flu vaccine. Compared to conventional injectable vaccines, NasoVAX offers faster action and does not require a nurse. NasoShield, an intranasally administered anthrax vaccine, is another well-known product from Altimmune. The company has also developed COVID-19 vaccine candidates that are now being tested in clinical trials. Altimmune aims to develop innovative solutions for serious diseases. The company has a strong commitment to research and development and is committed to continuing its successes in drug development. The company's mission is to ensure the creation of cost-effective solutions and improvement of outcomes for patients. Through the development of novel therapies and vaccines, Altimmune is repeatedly praised as one of the most promising companies in the industry. With a growing product range and a strong research and development department, the company is well-equipped to tackle important medical challenges of the future. In the future, it will be of great importance for Altimmune to continue developing innovative products that meet medical requirements. The industry will evolve through new scientific discoveries and the use of cutting-edge technologies, and Altimmune strives to play a leading role in this transformation.
The revenue cannot currently be calculated for Altimmune.
The expected profit of Altimmune is -40.71 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Altimmune is currently -8.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Altimmune stock.
The P/S cannot be calculated for Altimmune currently.
The Eulerpool Quality Score for Altimmune is 3/10.
The ISIN of Altimmune is US02155H2004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Altimmune is A2N5Z6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Altimmune is ALT. The ticker symbol is used to trade Altimmune shares on the stock exchange.
The current dividend yield of Altimmune is 26,697.25 %.
Altimmune paid dividends every year for the past 0 years.
Altimmune is assigned to the 'Health' sector.
To receive the latest dividend of Altimmune from amounting to 873 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Altimmune are distributed in USD.
Altimmune stock
Altimmune Peer Group
Altimmune Ticker
Altimmune FIGI
All fundamentals and in-depth analysis of Altimmune
Our stock analysis for Altimmune stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Altimmune. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.